The European Medicines Agency Committee for
Medicinal Products for Human Use (CHMP) has adopted a positive opinion
recommending a variation to the terms of the marketing authorization for
the medicinal product abiraterone (Zytiga). The CHMP adopted a new indication as follows: "ZYTIGA
is indicated with prednisone or prednisolone for: the treatment of
metastatic castration resistant prostate cancer in adult men who are
asymptomatic or mildly symptomatic after failure of androgen deprivation
therapy in whom chemotherapy is not yet clinically indicated". Read more here.
No comments:
Post a Comment